Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm

Journal of Clinical Pharmacology

Volumn 55, Issue 9, 2015, Pages 1051-1060

  Krösser, Sonja ^a   Wolna, Peter ^a   Fischer, Tanya Z ^b   Boschert, Ursula ^b   Stoltz, Randall ^c   Zhou, Meijian ^d   Darpo, Borje ^d,e  

^a MERCK KGAA   (Germany)

^b EMD SERONO INC   (United States)

^c Covance ^*  (United States)

^d ICardiac Technologies   (United States)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

heart rate; lymphocyte count; pharmacodynamics; sphingosine 1 phosphate

Indexed keywords

CERALIFIMOD; FINGOLIMOD; PLACEBO; AZETIDINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; NAPHTHALENE DERIVATIVE;

ABSCESS; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEART FUNCTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PR INTERVAL; RANDOMIZED CONTROLLED TRIAL; URTICARIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; BLOOD; DRUG EFFECTS; HALF LIFE TIME; HEART; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FINGOLIMOD HYDROCHLORIDE; HALF-LIFE; HEART; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MALE; MIDDLE AGED; NAPHTHALENES; YOUNG ADULT;

EID: 84937727626     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.513     Document Type: Article

References (26)

1. Komiya T, Sato K, Shioya H, et al., Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol. 2013; 171: 54-62.
2. van Doorn, R, Lopes, Pinheiro, MA, Kooij, G, et al., Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuroinflammation. 2012; 9: 133.
3. Zipp F, Vollmer T, Bar-Or A, et al., on behalf of the DreaMS study investigators. Relapse rates in patients with multiple sclerosis receiving ONO-4641, a sphingosine-1-phosphate receptor agonist: interim results from an extension of the DreaMS study. Mult Scler J. 2013; 19 (Suppl 1): 454-455.
4. Vollmer T, Zipp F, Bar-Or A, Due B, Thangavelu K, Fischer TZ, on behalf of the DreaMS study investigators. Magnetic resonance imaging measures of efficacy in patients with multiple sclerosis receiving ONO-4641, a sphingosine-1-phosphate receptor-1 and -5 agonist: interim results from an extension of the DreaMS study. Mult Scler J. 2013; 19 (Suppl 1): 226-227.
5. Scott LJ. Fingolimod:, a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs. 2011; 25: 673-698.
6. Cohen JA, Chun J., Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011; 69: 759-777.
7. Center for Drug Evaluation and Research. Medical review; Fingolimod, Application Number 22-527; Washington, DC; 2010.
8. Nada A, Gintant GA, Kleiman R, et al., The evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development. Am Heart J. 2013; 165: 489-500.
9. Schmouder R, Hariry S, David OJ., Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 2012; 68: 355-362.
10. Schmouder R, Serra, D, Wang, Y, Kovarik, JM, DiMarco, J, Hunt, TL, Bastien, MC., FT Y720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006; 46: 895-904.
11. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G,. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004; 57: 586-591.
12. Center for Drug Evaluation and Research. Cross discipline team leader review; Fingolimod, Application Number 22-527, Washington, DC; 2010.
13. Kovarik JM, Hartmann S, Bartlett M, et al., Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos. 2007; 28: 97-104.
14. Lee JY, Wang Y., Use of a biomarker in exposure-response analysis to support dose selection for fingolimod. CPT Pharmacometrics Syst Pharmacol. 2013; 2: e67.
15. Savinainen A, El Bawab S, Crandall T, Chang R, Boschert U, Dellovade T,. ONO-4641, potent and selective sphingosine 1 phosphate receptor-1 and -5 agonist, requires less lymphopenia than fingolimod to be effective in a preclinical model of multiple sclerosis. Mult Scler J. 2013; 19 (Suppl 1): 235-236.
16. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA., Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006; 180: 63-70.
17. Sospedra M, Martin R., Immunology of multiple sclerosis. Annu Rev Immunol. 2005; 23: 683-747.
18. Lehmann-Horn K, Kronsbein HC, Weber MS., Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord. 2013; 6: 161-173.
19. Mayol K, Biajoux V, Marvel J, Balabanian K, Walzer T., Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. Blood. 2011; 118: 4863-4871.
20. Han S, Lin YC, Wu T, et al., Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol. 2014; 192: 2551-2563.
21. Bertouch JV, Roberts-Thomson PJ, Bradley J., Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. Br Med J (Clin Res Ed). 1983; 286: 1171-1172.
22. Brossard P, Derendorf, H, Xu, J, Maatouk, H, Halabi, A, Dingemanse, J., Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013; 76: 888-896.
23. Brossard P, Scherz M, Halabi A, Maatouk H, Krause A, Dingemanse J., Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol. 2014; 54: 179-188.
24. Selmaj K, Li DK, Hartung HP, et al., Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013; 12: 756-767.
25. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al., The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012; 167: 1035-47.
26. US Food and Drug Administration. Prescribing information (fingolimod). Washington, DC; 2012.